BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu YJ, Zhang P, Hu JL, Liang H, Zhu YY, Cui Y, Niu P, Xu M, Liu MY. Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness. World J Gastrointest Oncol 2022; 14(4): 920-934 [PMID: 35582108 DOI: 10.4251/wjgo.v14.i4.920] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 . Antineoplastics. Reactions Weekly 2022;1913:61-61. [DOI: 10.1007/s40278-022-18211-x] [Reference Citation Analysis]